However, it should be noted that the median follow-up of the SCCLG-ALL-2016 protocol in this study was less than 5 years, and it has been reported in the literature (8) that ETV6/RUNX1-positive pediatric patients are prone to late relapses, with 80% of relapsed cases presenting 6 years after diagnosis carrying the ETV6/RUNX1 fusion gene. Here, RUNX1 is linked to acute lymphoblastic leukemia.